SELECT * FROM `stock_list` where symbol='B1MR34' AND exchange = 'BSP' limit 0,1
SELECT * FROM `stock_list` where symbol='B1MR34' AND exchange = 'BSP' limit 0,1
SELECT * FROM `stock_list` WHERE `symbol` = "B1MR34" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 Biomarin Pharmaceutical (BSP:B1MR34) Cash Receipts from Ope
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cash Receipts from Operating Activities

Biomarin Pharmaceutical (BSP:B1MR34) Cash Receipts from Operating Activities


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Cash Receipts from Operating Activities?

Cash Receipts from Operating Activities only applicable to companies reporting Cash Flow from Operations in direct method.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cash Receipts from Operating Activities
Comparable Companies
BGNE ALNY RPRX SRPT INCY UTHR TECH BNTX ROIV LEGN OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX OCSE:GMAB
Traded in Other Exchanges
BMRN:USA 1BMRN:Italy BM8:Germany
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.